Home | Contact Us

• HOME
• ABOUT US
• PRODUCTS
• NEWS & PUBLICATIONS
• CAREERS
• CONTACT

Latest News

1.28.10 Alnara Pharmaceuticals Secures $35 Million in Series B Round

For more information click here

1.6.10
Alnara Pharmaceuticals to Present at 28th Annual J.P. Morgan Healthcare Conference.

11.3.09
Alnara Pharmaceuticals Announces Appointment of Lee R. Brettman, M.D., FACP, to Chief Medical Officer.

10.21.09
Lonza and Alnara Pharmaceuticals Enter into Manufacturing Agreement to Produce Liprotamase.

10.19.09
Alnara Pharmaceuticals’ Liprotamase Demonstrates Long-Term Safety & Maintenance of Nutritional Status in Patients with CF; Results of Landmark Phase 3 Safety Study Reported.

10.5.09
Long-Term Data from Landmark Phase 3 Safety and Nutritional
Study Evaluating Alnara Pharmaceuticals’ Liprotamase in Patients
with CF to be Presented at 2009 North American Cystic Fibrosis Conference.

6.2.09
Alnara Pharmaceuticals to Present at Goldman Sachs
Global Healthcare Conference.

4.16.09
Alnara Pharmaceuticals Announces Promotion of Robert Gallotto
to Chief Business Officer.

3.25.09
Alnara Pharmaceuticals Licenses Worldwide Rights to Liprotamase
from Cystic Fibrosis Foundation.

10.30.08
Alnara Pharmaceuticals, Inc. has announced that it has secured
$20 million in Series A venture capital financing.

Media Inquiries

Michele Rozen
Pure Communications
617-730-8284

© Alnara Pharmaceuticals. All rights reserved.